Marten J. Poley - Erasmus Universiteit Rotterdam

84Chapter 533. Meinert CL: Extracorporeal membraneoxygenation trials. Pediatrics 1990;85(3): 365-366.34. Paneth N, Wallenstein S: Extracorporealmembrane oxygenation and the play thewinner rule. Pediatrics 1985; 76(4):622-623.35. Ware JH, Epstein MF: Extracorporealcirculation in neonatal respiratoryfailure: a prospective randomized study.Pediatrics 1985; 76(5): 849-851.36. Hilhorst MT: The ethical assessment ofnew technologies: the case of ECMO. InMisbin RI, Jennings B, Orentlicher D,Dewar M (eds): Health care crisis? Thesearch for answers. Frederick, Maryland:University Publishing Group; 1995.37. Krummel TM, Greenfield LJ, KirkpatrickBV, Mueller DG, Ormazabal M, SalzbergAM: Clinical use of an extracorporealmembrane oxygenator in neonatalpulmonary failure. J Pediatr Surg 1982;17(5): 525-531.38. Beck R, Anderson KD, Pearson GD,Cronin J, Miller MK, Short BL: Criteria forextracorporeal membrane oxygenationin a population of infants with persistentpulmonary hypertension of the newborn.J Pediatr Surg 1986; 21(4): 297-302.39. Toomasian JM, Snedecor SM, Cornell RG,Cilley RE, Bartlett RH: Nationalexperience with extracorporealmembrane oxygenation for newbornrespiratory failure. Data from 715 cases.ASAIO Trans 1988; 34(2): 140-147.40. Michel BC, Staveren RJEv, Hout BAv:ECMO. A survey of the cost-effectivenessof extracorporeal membraneoxygenation in neonates compared toconventional therapy [in Dutch]. InFesten C, Sengers RCA, Geven WB,Staak FHJvd, Schöller M, Fons G, et al(eds): Final report of the DutchInvestigative Medicine Program'Extracorporeal Membrane Oxygenation(ECMO) in neonates (OG 90-001)'.Nijmegen/Rotterdam: AcademischZiekenhuis Nijmegen/AcademischZiekenhuis Rotterdam/ErasmusUniversiteit Rotterdam; 1995.41. Dos Santos Silva I: Cancerepidemiology: principles and methods.Lyon, France: International Agency forResearch on Cancer; 1999.42. Ramsay CR, Grant AM, Wallace SA,Garthwaite PH, Monk AF, Russell IT:Assessment of the learning curve inhealth technologies. A systematicreview. Int J Technol Assess Health Care2000; 16(4): 1095-1108.43. Health Insurance Board: Guidelines forpharmacoeconomic evaluations [inDutch]. Amstelveen: Health InsuranceBoard; 1999.44. Briggs AH, Gray AM: Handlinguncertainty when performing economicevaluation of healthcare interventions.Health Technol Assess 1999; 3(2): 1-134.45. Boyle MH, Torrance GW, Sinclair JC,Horwood SP: Economic evaluation ofneonatal intensive care of very-lowbirth-weightinfants. N Engl J Med 1983;308(22): 1330-1337.46. Doyle LW: Evaluation of neonatalintensive care for extremely low birthweight infants in Victoria over twodecades: II. Efficiency. Pediatrics 2004;113(3 Pt 1): 510-514.47. Lorch SA, Cnaan A, Barnhart K: Costeffectivenessof inhaled nitric oxide forthe management of persistentpulmonary hypertension of the newborn.Pediatrics 2004; 114(2): 417-426.48. Phibbs CS, Phibbs RH, Wakeley A,Schlueter MA, Sniderman S, Tooley WH:Cost effects of surfactant therapy forneonatal respiratory distress syndrome.J Pediatr 1993; 123(6): 953-962.49. Rogowski J: Cost-effectiveness of carefor very low birth weight infants.Pediatrics 1998; 102(1): 35-43.50. Tubman TRJ, Halliday HL, Normand C:Cost of surfactant replacementtreatment for severe neonatalrespiratory distress syndrome: arandomised controlled trial. Br Med J1990; 301(6756): 842-845.